San Diego-based Ambit Biosciences has filed for an IPO, saying in an S-1 with the SEC that it is looking to raised $57.5M in a funding round. The firm said it intends to list as AMBI on the Nasdaq Global Market. The IPO is being underwritten by Citigroup, Leerink Swann, BMO Capital Markets, and Baird.
Ambit Biosciences is venture backed by Apposite Healthcare Fund, Forward Ventures, GIMV, GrowthWorks, MedImmune Ventures, OrbiMed, Perseus-Soros Biopharmaceutical Fund, Roche, along with others. The IPO filing comes two years after Ambit dropped an earlier, IPO bid, due to lack of interest in the public markets.